An open-label Phase III trial showed that participants using Zepbound saw 47% greater relative weight loss compared to Wegovy.

Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia ...

Eli Lilly's Zepbound outperformed Wegovy in weight loss and key outcomes during the SURMOUNT-5 trial, showing a comparable ...

Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.

Eli Lilly said on Wednesday that a clinical trial had shown that patients taking its weight-loss drug Zepbound (tirzepatide) ...

Heart failure outcomes in patients with type 2 diabetes receiving once-weekly exenatide are affected by left ventricular ejection fraction.

The rise of weight loss drugs is not only changing individual lives, but also reshaping large sections of the economy.

The connection between weight loss medications and addiction reduction represents a potentially transformative discovery in ...

As anti-obesity medications gain popularity, a new concern has also gained traction among researchers: increased food waste. A self-administered online survey sponsored by Ohio State found that 25% of ...

About one-third of US adults without diabetes who are eligible for weight loss treatment with GLP-1 receptor agonists and GLP-1/GIP receptor agonists meet exclusion criteria for clinical trials.

Neurotone AI, pioneer in aural rehabilitation, and creator of Lace AI Pro, today announced it has entered into a definitive agreement to acquire Amptify, a leading digital hearing healthcare platform ...